There is only one therapy approved for the treatment of malignant mesothelioma, a combination chemotherapy of pemetrexed and cisplatin. Median survival with the best standard of care is 12 months after diagnosis.

For more information on pleural mesothelioma:

Pivotal phase II/III study

Six mesothelioma referral centers in five European countries are participating in a pivotal clinical phase II/III study. The study is named DENIM: DENdritic Cell Immunotherapy for Mesothelioma.

The DENIM study is an open-label, randomised, phase II/III study in adults with pleural mesothelioma, to assess the efficacy and anti-tumour activity of MesoPher as maintenance treatment after chemotherapy. Additionally, safety, tolerability, quality of life and immunogenicity of MesoPher will be evaluated.

Amphera is the sponsor of the DENIM study. The DENIM study has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 668769.

For more information on the DENIM study: